We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2) (PROGENI)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01536821
First Posted: February 22, 2012
Last Update Posted: December 16, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Michael J. Fox Foundation for Parkinson's Research
Information provided by (Responsible Party):
Indiana University
February 16, 2012
February 22, 2012
December 16, 2013
May 2011
December 2013   (Final data collection date for primary outcome measure)
Observation and biological specimen collection [ Time Frame: 1 time ]
Not Provided
Complete list of historical versions of study NCT01536821 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study of LRRK2 (Leucine-rich Repeat Kinase 2)
PROGENI (Parkinson's Research: The Organized Genetics Initiative) Family Study
The PROGENI Family Study is part of a larger consortium that is studying a gene shown to be important in Parkinson's disease, called LRRK2. People who have a defect in the LRRK2 gene will often develop Parkinson's disease. Eligible participants will be asked to complete a single Study Visit at an affiliated research facility closest to their home.

Participants will be asked to complete a family history questionnaire, which will gather information about their family history of Parkinson's disease and related disorders. They will be asked to complete a single Study Visit, during which they will be asked to do some or all of the following:

  1. Complete questionnaires regarding Parkinson's disease symptoms, medical history, mood, sleep, mental status, and activity level.
  2. Be given a brief standard neurological examination.
  3. Be given a scratch and sniff smell identification test.
  4. Be asked to give a sample of approximately 2 tablespoons of blood.
  5. Be asked to give a urine sample of approximately 1 tablespoon of urine.
Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
Description:
DNA, plasma and serum will be obtained and stored from a blood sample. In addition, a whole blood and urine samples will be obtained and stored.
Non-Probability Sample
Participants must provide test results documenting a LRRK2 mutation.
Parkinson Disease
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
81
December 2013
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Positive for a LRRK2 mutation

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Canada,   United States
 
 
NCT01536821
1105005340
Yes
Not Provided
Not Provided
Indiana University
Indiana University
Michael J. Fox Foundation for Parkinson's Research
Principal Investigator: Tatiana Foroud, PhD Indiana University
Indiana University
April 2013
To Top